DOI: 10.1128/AAC.00633-16
Article Information
PubMed
Published By
History
- Received April 6, 2016
- Returned for modification April 28, 2016
- Accepted July 31, 2016
- Published online September 23, 2016.
Copyright & Usage
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (August 08, 2016).
- You are viewing the most recent version of this article.
Author Information
- Christopher Lucastia,
- Liviu Vasileb,
- Dorel Sandescc,
- Donatas Venskutonisd,
- Patrick McLerothe,
- Mallika Lalaf,
- Matthew L. Rizkf,
- Michelle L. Brownf,
- Maria C. Losadaf,
- Alison Pedleyf,
- Nicholas A. Kartsonisf and
- Amanda Paschkef
- aSouth Jersey Infectious Disease, Somers Point, New Jersey, USA
- bUniversity of Medicine & Pharmacy, Craiova, Romania
- cUniversity of Medicine & Pharmacy, Timisoara, Romania
- dLithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania
- eCovance Inc., Princeton, New Jersey, USA
- fMerck & Co., Inc., Kenilworth, New Jersey, USA
- Address correspondence to Amanda Paschke, amanda.paschke{at}merck.com.
Citation Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A. 2016. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 60:6234–6243. doi:10.1128/AAC.00633-16.
